Sorrento Therapeutics (SRNE) Receives Price Target

Sorrento Therapeutics (SRNE) : Currently there are 4 street experts covering Sorrento Therapeutics (SRNE) stock. The most bullish and bearish price target for the stock is $30 and $10 respectively for the short term. The average price target of all the analysts comes to $17.5. The estimated standard deviation from the target is $8.66.


Sorrento Therapeutics (NASDAQ:SRNE): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.70 and $6.55 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.76, notching a gain of 1.50% for the day. The total traded volume was 101,139 . The stock had closed at $6.66 on the previous day.

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics for addressing unmet medical needs in the United States, Europe, as well as international markets. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but it is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Cynviloq and resiniferatoxin (RTX), a non-opiate, ultra-potent and selective agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV-1) receptor. Its pipeline also includes preclinical human therapeutic monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast (CAR.TNK) for adoptive cellular immunotherapies (ACI).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.